Module 3 for Biological Medicines: Cell Banks, Viral Safety and Comparability

The CTD quality structure was first written with small molecules in mind, but biological medicines place very different demands on Module 3. Cell substrates, viral safety, characterisation of a heterogeneous molecule and the management of process changes all need to be addressed through the ICH Q5 and Q6B guidelines.

Control of materials and cell banks

For a biotechnology-derived active substance, the control of materials section (3.2.S.2.3) carries far more weight than for a chemical synthesis. It should describe the origin and history of the cell line, the generation of the expression construct and the cell banking system. ICH Q5D sets expectations for deriving and characterising cell substrates, and ICH Q5B addresses analysis of the expression construct and genetic stability.

Viral safety

ICH Q5A(R2), the revised guideline on viral safety evaluation of biotechnology products, extends its scope and updates expectations on testing and viral clearance. A complete viral safety package typically combines:

  • testing of cell banks and unprocessed bulk for adventitious viruses;
  • control of raw materials of biological origin;
  • viral clearance studies demonstrating the capacity of selected process steps to remove or inactivate viruses.

This evidence is summarised in the adventitious agents appendix (3.2.A.2) and should be consistent with the process description.

Characterisation and specifications

Biological products are inherently heterogeneous. ICH Q6B expects characterisation of physicochemical properties, biological activity, immunochemical properties, purity and impurities, including product-related variants and process-related impurities such as host cell proteins and DNA. Specifications should be justified by this characterisation, by batch data and by the material used in clinical studies. A potency assay that reflects the mechanism of action is central.

Managing change through comparability

Manufacturing processes for biologics evolve throughout development and after approval. ICH Q5E describes how to demonstrate that pre- and post-change product are comparable, using a stepwise approach that begins with analytical comparison and adds nonclinical or clinical data only where needed. A well-documented development history in 3.2.S.2.6 makes these exercises far easier to present.

Stability

Stability programmes for biologics need to capture changes in potency, aggregation and degradation that may not be detected by simple assays. ICH Q5C has long set these expectations, and the ongoing revision of the ICH stability guideline is bringing stability requirements for chemical and biological products under a single framework.

How PQRA helps

PQRA supports developers of biological medicines with Module 3 authoring and gap analysis, including cell bank documentation, viral safety summaries and comparability protocols.

Contact PQRA to discuss your next dossier.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Leave a Reply

Your email address will not be published. Required fields are marked *